Morisset Valerie
Known title: EVP, R&D and CSOCIK: 0001868517
Associated companies
Transaction History
| CLYM | ▼ Sell | Open Market | 39,005 | $315K | 7/22/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 30,000 | $239K | 7/22/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 10,201 | $72K | 7/19/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 50,000 | $362K | 7/19/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 38,576 | $267K | 7/18/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 3,207 | $22K | 7/17/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 50,000 | $357K | 7/16/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 42,377 | $297K | 7/15/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 50,000 | $354K | 7/12/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 50,000 | $356K | 7/11/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 50,000 | $342K | 7/10/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 5,931 | $40K | 7/9/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 12,342 | $87K | 7/5/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 50,000 | $338K | 7/3/2024 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 7,649 | $2 | 7/1/2024 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 17,847 | $4 | 4/5/2024 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 5,431 | $11 | 9/20/2023 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 15,297 | $3 | 9/20/2023 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 255,219 | $510 | 3/10/2023 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 61,191 | $12 | 3/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets
Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.
Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets. Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.